This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- SP-8203
- DrugBank Accession Number
- DB11670
- Background
SP-8203 has been used in trials studying the treatment of Ischemic Stroke.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for SP-8203 (DB11670)
- Weight
- Average: 534.617
Monoisotopic: 534.259068219 - Chemical Formula
- C28H34N6O5
- Synonyms
- Not Available
- External IDs
- J3.046.690J
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as quinazolines. These are compounds containing a quinazoline moiety, which is made up of two fused six-member aromatic rings, a benzene ring and a pyrimidine ring.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Diazanaphthalenes
- Sub Class
- Benzodiazines
- Direct Parent
- Quinazolines
- Alternative Parents
- Pyrimidones / Benzenoids / Vinylogous amides / Tertiary carboxylic acid amides / Heteroaromatic compounds / Acetamides / Ureas / Lactams / Amino acids and derivatives / Dialkylamines show 4 more
- Substituents
- Acetamide / Amine / Amino acid or derivatives / Aromatic heteropolycyclic compound / Azacycle / Benzenoid / Carbonyl group / Carboxamide group / Carboxylic acid derivative / Heteroaromatic compound show 15 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- UYE03B60KA
- CAS number
- 1176758-04-5
- InChI Key
- SJZBPVOSFYUHFV-UHFFFAOYSA-N
- InChI
- InChI=1S/C28H34N6O5/c1-20(35)32(17-9-19-34-26(37)22-11-3-5-13-24(22)31-28(34)39)16-7-6-14-29-15-8-18-33-25(36)21-10-2-4-12-23(21)30-27(33)38/h2-5,10-13,29H,6-9,14-19H2,1H3,(H,30,38)(H,31,39)
- IUPAC Name
- N-[3-(2,4-dioxo-1,2,3,4-tetrahydroquinazolin-3-yl)propyl]-N-(4-{[3-(2,4-dioxo-1,2,3,4-tetrahydroquinazolin-3-yl)propyl]amino}butyl)acetamide
- SMILES
- CC(=O)N(CCCCNCCCN1C(=O)NC2=CC=CC=C2C1=O)CCCN1C(=O)NC2=CC=CC=C2C1=O
References
- General References
- Not Available
- External Links
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data3 Not Yet Recruiting Treatment Ischemic Stroke 1 somestatus stop reason just information to hide 2 Completed Treatment Ischemic Stroke 2 somestatus stop reason just information to hide 1 Completed Treatment Ischemic Stroke 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0671 mg/mL ALOGPS logP 1.78 ALOGPS logP 2.33 Chemaxon logS -3.9 ALOGPS pKa (Strongest Acidic) 11.16 Chemaxon pKa (Strongest Basic) 10.13 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 6 Chemaxon Hydrogen Donor Count 3 Chemaxon Polar Surface Area 131.16 Å2 Chemaxon Rotatable Bond Count 13 Chemaxon Refractivity 149.63 m3·mol-1 Chemaxon Polarizability 57.42 Å3 Chemaxon Number of Rings 4 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 209.04167 predictedDeepCCS 1.0 (2019) [M+H]+ 211.39967 predictedDeepCCS 1.0 (2019) [M+Na]+ 218.05183 predictedDeepCCS 1.0 (2019)
Drug created at October 20, 2016 20:38 / Updated at June 12, 2020 16:53